// App-Quantinova.ai

: Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study

Researchers

Presenter

  • Anthony R Mato

Principal Investigators

  • Brian T. Hill

  • Mazyar Shadman

  • Hande Tuncer

  • Allison M. Winter

  • Kaitlin Kennard

  • John N. Allan

  • Chaitra S. Ujjani

  • Danielle M. Brander

  • Chadi Nabhan

  • Paul Barr

  • Jennifer R. Brown

  • Christopher P. Fox

  • Joanna Rhodes

  • Anna Schuh

  • Toby A. Eyre

  • Nicole Lamanna

  • Nitin Jain

  • William G. Wierda

  • Alan P Skarbnik

  • Lindsey E. Roeker

  • Rajat Bannerji

  • Andrew M. Evens

  • Frederick Lansigan

  • Jennifer C. Samp

  • Jacqueline Nielsen

  • James M. Pauff

  • Thomas J. Kipps

  • Stephen J. Schuster

  • George A Follows

  • Bruce Cheson

  • Barbara Eichhorst

Medical Centers

  • Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Neurology, Medstar Georgetown University Hospital, Washington DC, DC

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Tufts Medical Center, Boston, MA

  • Cleveland Clinic, Cleveland, OH

  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

  • Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Cardinal Health Specialty Solutions, Deerfield, IL

  • University of Rochester, Rochester, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

  • Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Churchill Hospital, Oxford University Hospital, Oxford, United Kingdom,

  • Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ

  • Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Dartmouth Hitchcock Medical Center, Lebanon, NH

  • AbbVie, Inc., North Chicago, IL

  • AbbVie, Inc., North Chicago, IL

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • Haematology, Cambridge University Hospitals NHS Foundation Trust (on behalf of the UK CLL forum), Cambridge, United Kingdom

  • Georgetown University Hospital Lombardi Cancer Center, Washington, DC

  • University of Cologne, Cologne, DE, Germany

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Idelalisib

  • Venetoclax

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved